Bedfont Logo
Smokerlyzer
NObreath
Gastrolyzer
MediGas Check
ToxCO

Bedfont Logo

Bedfont brings the 2nd generation NObreath to the GCC

Bedfont brings the 2nd generation NObreath to the GCC

Bedfont Scientific Ltd. is exhibiting its wide range of medical devices at Arab Health 2019, including its new and improved NObreath® FeNO monitor

Breath analysis medical device manufacturer, Bedfont, will be returning to Arab Health 2019 – the largest healthcare exhibition in the Gulf Cooperation Council. They will be exhibiting their wide range of breath analysis medical devices, including the new and improved NObreath® FeNO monitor.

The NObreath® offers a quick, simple and non-invasive method of measuring FeNO to assess airway inflammation, aiding in the diagnosis and management of asthma. Interpreting FeNO levels aids in identifying patients who do/do not require on-going treatment1 whilst also differentiating between allergic (eosinophilic) and non-allergic asthma2, and if used daily, FeNO measurements can help to predict exacerbations and attacks3.

Alongside a fresh and aesthetically pleasing design with a full-colour touchscreen, new features of the 2nd generation NObreath® also include the ability to save patient profiles on the device, Bluetooth connectivity, and SteriTouch® technology for optimum infection control. Furthermore, the NObreath® comes with free patient management software allowing the equipment to synchronise with a PC, enabling reports to be generated, data to be backed up, and much more.

Established in 1976, their other monitors include the Smokerlyzer®, used for smoking cessation, and the ToxCO®, used by emergency services, to screen for CO poisoning. The Gastrolyzer® range aids in the detection of gastrointestinal disorders and food intolerances.

Matthew Skinner, Sales Team Manager, said, “Bedfont aims to continue improving and innovating health, and being the largest healthcare gathering in the GCC, Arab Health is the perfect place to find like-minded companies to work with and help raise awareness of the benefits of breath testing.”

This year, Arab Health is taking place between 28-31 January in Dubai and Bedfont can be found at stand C57, Hall 7.

REFERENCES
  1. Andrew D. Smith, Jan O. Cowan, Sue Filsell, Chris MacLachlan, Gabrielle Monti-Sheehan, Pamela Jackson and D. Robin Taylor. Diagnosing Asthma: Comparisons between Exhaled Nitric Oxide Measurements and Conventional Tests. Am J Respir Crit Care Med Vol 169. pp 473-478, 2004.
  2. Coumou HBel E. Improving the diagnosis of eosinophilic asthma [Internet]. Taylor and Francis online. 2017 [cited 15 March 2017]. Available from: http://www.tandfonline.com/doi/full/10.1080/17476348.2017.1236688
  3. Harkins M. Exhaled Nitric Oxide Predicts Asthma Exacerbation [Internet]. Taylor & Francis. 2017 [cited 21 September 2017]. Available from: http://www.tandfonline.com/doi/abs/10.1081/JAS-120033990




« BACK

I AM INTERESTED IN

I AM A

News Filters

>